TrialOncotarget2015

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Amir Sonnenblick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.